3 Under-the-Radar Stocks to Buy and Hold for a Decade
All three could become highly prominent biotech companies within 10 years.
3 Under-the-Radar Stocks to Buy and Hold for a Decade
Overview
It isn't only the most popular stocks that deliver strong returns. There are plenty of little-known corporations with attractive prospects that can be great additions to a well-diversified portfolio for investors who take the time to find them. In that spirit, let's consider three under-the-radar companies that are worth a second look right now: Madrigal Pharmaceuticals (NASDAQ: MDGL), Axsome Therapeutics (NASDAQ: AXSM), and Kailera Therapeutics (NASDAQ: KLRA). These three biotechs could offer attractive returns over the next decade.
Image source: Getty Images.
Madrigal Pharmaceuticals made history in 2024 when it earned approval for Rezdiffra, the first medicine for metabolic dysfunction-associated steatohepatitis (MASH). There was a dire need for a treatment for MASH when Madrigal first entered the field: Millions of patients in the U.S. alone suffer from the disease. Sure enough, Madrigal Pharmaceuticals has made significant headway in this market. As of March 31, more than 42,250 patients were being treated with Rezdiffra. Madrigal Pharmaceuticals' first-quarter revenue increased by 127% year over year to $311.3 million, driven by Rezdiffra, the company's only approved medicine.
Details
Source
Originally published at www.fool.com.
